| Name | Title | Contact Details |
|---|
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.
Viral Sensitizers (VSE) for drug developers and manufacturers are small molecules that improve viral yields and effectiveness by reducing the antiviral defences on a cellular level.
Celcuity is a biotech company developing state-of-the-art cell-based assays using our proprietary functional cellular analysis platform.
Onconome is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
University Technologies International is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, and Biotech sector.